Table 8.

Tabular summary

Efalizumab
First approved in Germany	September 2004 (psoriasis vulgaris)
Recommended control parameters	Prior to therapy exclusion of significant infections, complete blood count, liver values
Recommended initial dosage	0.7 mg/kg body weight (BW) per week
Recommended maintenance dosage	1 mg/kg BW per week
Expected beginning of clinical effect	After 4–8 weeks
Response rate	PASI 75 for approximately 30% of the patients after 12 weeks (LE 1)
Important contraindications (limited selection)	Chronic or acute infections, pregnancy, malignant diseases, immune deficiencies, no vaccinations before or during treatment
Important ADRs (limited selection)	Flu-like injection reactions, leukocytosis and lymphocytosis, rebound, exacerbation and arthralgia, thrombocytopenia
Important drug interactions	Not known
Other	Stop therapy due to the risk of exacerbation and rebound if a PASI reduction of 50% is not achieved after 12 weeks